Haemophilia registry of the Medical Committee of the Swiss Hemophilia Society. Update and annual survey 2010-2011.

Details

Serval ID
serval:BIB_89049A1DD479
Type
Inproceedings: an article in a conference proceedings.
Collection
Publications
Institution
Title
Haemophilia registry of the Medical Committee of the Swiss Hemophilia Society. Update and annual survey 2010-2011.
Title of the conference
42. Hamburger Hämophilie-Symposium
Author(s)
von der Weid N.
Address
Hamburg, Germany, November 11-12, 2011
ISBN
0720-9355 (Print)
ISSN-L
0720-9355
Publication state
Published
Issued date
2012
Volume
32
Series
Hämostaseologie
Pages
S20-S24
Language
english
Notes
Publication types: Journal ArticlePublication Status: ppublish
Abstract
The Haemophilia Registry of the Swiss Haemophilia Society was created in the year 2000. The latest records from October 31st 2011 are presented here. Included are all patients with haemophilia A or B and other inherited coagulation disorders (including VWD patients with R-Co activity below 10%) known and followed by the 11 paediatric and 12 adult haemophilia treatment or reference centers. Currently there are 950 patients registered, the majority of which (585) having haemophilia A. Disease severity is graded according to ISTH criteria and its distribution between mild, moderate and severe haemophilia is similar to data from other European and American registries. The majority (about two thirds) of Swiss patients with haemophilia A or B are treated on-demand, with only about 20% of patients being on prophylaxis. The figure is different in paediatrics and young adults (1st and 2nd decades), where 80 to 90% of patients with haemophilia A are under regular prophylaxis. Interestingly enough, use of factor concentrates, although readily available, is rather low in Switzerland, especially when taking the country's GDP into account: The total amount of factor VIII and IX was 4.94 U pro capita, comparable to other European countries with distinctly lower incomes (Poland, Slovakia, Hungary). This finding is mainly due to the afore mentioned low rate of prophylactic treatment of haemophilia in our country. Our registry remains an important instrument of quality control of haemophilia therapy in Switzerland.
Pubmed
Web of science
Create date
20/12/2012 18:53
Last modification date
20/08/2019 14:48
Usage data